Is tapentadol an advance on tramadol?

Consultant Pharmacist

Volumn 24, Issue 11, 2009, Pages 833-840

  Guay, David R P ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

Author keywords

Monoamine reuptake inhibitors; Opioid receptor agonists; Tapentadol

Indexed keywords

HYDROMORPHONE; MORPHINE; NUCYNTA; OPIATE; OXYCODONE; PLACEBO; TAPENTADOL; TRAMADOL; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; ARTHRALGIA; CHRONIC PAIN; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONFUSION; CONSTIPATION; DECREASED APPETITE; DIZZINESS; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EMBASE; FATIGUE; FOOD AND DRUG ADMINISTRATION; FRAIL ELDERLY; GLUCURONIDATION; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; INFORMATION; INSOMNIA; LETHARGY; LOW BACK PAIN; MEDLINE; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; RISK; SEROTONIN SYNDROME; SOMNOLENCE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS, OPIOID; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; PAIN; PHENOLS; RECEPTORS, OPIOID, MU; TRAMADOL;

EID: 70450278677     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2009.833     Document Type: Review

References (24)

1. Carter GT, Sullivan MD. Antidepressants in pain management. Curr Opin Invest Drugs 2002;3:454-458
2. 2 agonists. In Buschmann H, Christoph T, Friderichs E, Maul C, Sanderman B. eds. Analgesics. From Chemistry and Pharmacology to Clinical Application. Weinheim, Germany: Wiley-VHC; 2002:264-284
3. Ossipov MH, Malseed RT, Goldstein FJ. Augmentation of central and peripheral morphine analgesia by desipramine. Arch Int Pharmacodyn 1982;259:222-229 (Pubitemid 13244037)
4. Raffa RB, Friderichs E, Reimann W et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 1992;260:275-285
5. Lintz W, Erlacin S, Frankus E et al. Biotransformation of tramadol in man and animal. Arzneim Forsch 1981;31:1932-1943
6. Raffa RB, Friderichs E, Reimann W et al. Complementary and synergistic antinociceptive interaction between enantiomers of tramadol. J Pharmacol Exp Ther 1993;267:331-340 (Pubitemid 23325025)
7. Frink MC, Hennies HH, Englberger W et al. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneim Forsch 1996;46:1029-1036 (Pubitemid 26391736)
8. Poulsen L, Arendt-Nielsen L, Brosen K et al. The hypoanalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:636-644 (Pubitemid 27025910)
9. Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256
10. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 2004;19 Suppl 1:S21-S25. (Pubitemid 39386316)
11. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-1120
12. Tapentadol (Nucynta) product information. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals; November 2008.
13. Tzschentke TM, Christoph T, Kogel B et al. (-1-(1R,2R)-3-(3-dimethyl- amino-1-ethyl-2-methyl-propyl)-phenol hydrochloride) (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-276
14. Kneip C, Terlinden R, Beier H et al. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett 2008;2:67-75.
15. Terlinden R, Ossig J, Fliegert F et al. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007;32:163-169 (Pubitemid 350178517)
16. Kiang TKL, Ensom MHH, Chang TKH. UDP-glucuronosytransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97-132.
17. Oh C, Upmalis D, Okamoto A et al. Efficacy of tapentadol immediate release in patients with pain after bunioncctomy. Presented at the 27th Annual Scientific Meeting of the American Pain Society; Tampa, FL; May 8, 2008 (poster 229).
18. Afilalo M, Oh C, Okamoto A et al. Tapentadol immediate release compared with oxycodone immediate release for the relief of moderate-to-severe pain in patients with end stage joint disease. Presented at the 27th Annual Scientific Meeting of the American Pain Society; Tampa, FL; Mav 9, 2008 (poster 224).
19. Hartrick CT, Van Hove I, Stegmann JU et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31:260-271
20. Oh C, Upmalis D, Okamoto A et al. Tapentadol immediate release is associated with improved gastrointestinal tolerability compared with oxycodone immediate release over 90 days in patients with lower back or osteoarthritis pain. Presented at the 27th Annual Scientific Meeting of the American Pain Society; Tampa, FL; May 9, 2008 (poster 226).
21. Upmalis D, Okamoto A, Oh C et al. Symptoms of opioid withdrawal after discontinuation of tapentadol immediate-release, an analgesic with mu-opioid receptor agonism. Presented at the 27th Annual Scientific Meeting of the American Pain Society; Tampa, FL; May 9, 2008 (Poster 214).
22. Schedules of controlled substances: placement of tapentadol into schedule II. Federal Register 2009;74:23790-23793
23. Schedules of controlled substances: placement of tapentadol into schedule II. Federal Register 2009;74:7386-7388
24. Thompson AJ, Lummis SCR. The 5-HT3 receptor as a therapeutic target. Exp Opin Ther Targets 2007;11:527-540